Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 17;21:538. doi: 10.1186/s12935-021-02228-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — TDO2 expression correlated with liver cancer development. A Immunohistochemical staining of TDO2 in high stage (H-S) and low stage (L-S) tumor tissues from liver cancer patients. The intensity of TDO2 expression was calculated in each group (n = 8). The scale bar is 100 μm. B Immunohistochemical staining of IDO1 in high stage (H-S) and low stage (L-S) tumor tissues from liver cancer patients. The intensity of IDO1 expression was calculated in each group (n = 8). The scale bar is 100 μm. C The survival analysis of liver cancer patients divided into high TDO2 expression (n = 134) and low TDO2 expression (n = 136) groups using TCGA database. D Western blotting of TDO2 in SMC-7721/HepG2 and TDO2 overexpression SMC-7721/HepG2 cells. E The colony formation rates of SMC-7721/HepG2 (VEC) and TDO2 overexpression SMC-7721/HepG2 (OE) cells. F The cell proliferation of SMC-7721/HepG2 (VEC) and TDO2 overexpression SMC-7721/HepG2 (OE) cells using CCK-8 analysis. G The tumorigenic capability of SMC-7721 (VEC) and TDO2 overexpression SMC-7721 (OE) cells in immunodeficient mice. H The tumor volume of SMC-7721 (VEC) and TDO2 overexpression SMC-7721 (OE) bearing mice. *p < 0.05, **p < 0.01, n.s, no significant difference